| Field | Specification |
|---|---|
| Target | |
| Alternative names | BD 3 ELISA Kit; BD-3 ELISA Kit; BD3 ELISA Kit; beta 103 ELISA Kit; Beta defensin 103A ELISA Kit; Beta defensin 103A precursor ELISA Kit; Beta defensin 3 ELISA Kit; Beta-defensin 103 ELISA Kit; Beta-defensin 3 ELISA Kit; D103A_HUMAN ELISA Kit; DEF B3 ELISA Kit; DEFB 103 ELISA Kit; DEFB 103A ELISA Kit; DEFB 3 ELISA Kit; DEFB-3 ELISA Kit; DEFB103 ELISA Kit; DEFB103A ELISA Kit; DEFB103B ELISA Kit; DEFB3 ELISA Kit; Defensin ELISA Kit; Defensin beta 103A ELISA Kit; Defensin beta 3 ELISA Kit; Defensin like protein ELISA Kit; Defensin-like protein ELISA Kit; HBD 3 ELISA Kit; hBD-3 ELISA Kit; HBD3 ELISA Kit; HBP 3 ELISA Kit; HBP3 ELISA Kit; mBD3 ELISA Kit |
| UniProt # | |
| Species | |
| Reactivity | |
| Applications | |
| Assay type | |
| Sample type(s) | serum, plasma, urine, cell culture supernates, tissue homogenates |
| Sensitivity | |
| Detection range | |
| Detection wavelength | |
| Assay time | |
| Catalog no. (Mfr.) | |
| Main SKU |
Background
β-defensins 3 (DEFB103A) is a biological molecule commonly studied in immunology research. It is commonly used as a molecular readout in mechanistic and biomarker-focused studies.
UniProt: P81534
Biological context
Researchers often monitor β-defensins 3 in serum, plasma, urine, and cell culture supernates to better understand themes such as innate and adaptive immune responses, cytokine signaling networks, and host–pathogen interactions. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in β-defensins 3 may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, cytokines, chemokines, acute-phase proteins, and immune-cell activation markers) and by keeping pre-analytical variables consistent across groups.
Nomenclature
In publications and databases, β-defensins 3 may also appear under names such as BD 3 and BD-3. When comparing studies, confirm that the reported analyte refers to the same molecule and species context.
Why ELISA data are widely used
ELISA is a common approach for quantitative measurement of proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that β-defensins 3 participates in.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Dynamic changes of Th1/Th2/Th17 cytokines and hBD-2/3 in erosive oral lichen planus patients saliva before and after prednisone acetate treatment
M Xie,Heliyon,2024
Evaluation of human β‑defensins in the cerebrospinal fluid of suspected meningitis
LK Jaleel,Biomedical Reports,2022
Multi-functional vesicles improve Helicobacter pylori eradication by a comprehensive strategy based on complex pathological microenvironment
X Chen,Acta Pharmaceutica Sinica B,2022
The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells
Cho MJ, et al,Biochemical and biophysical research communications,2018
Salivary human beta defensins affected by oral Candida status in Chinese HIV/AIDS patients undergoing ART
Liu Z.et al,Oral Dis,2018